[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"anaplastic-large-cell-lymphoma-alk-positive\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:anaplastic-large-cell-lymphoma-alk-positive":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,101,137],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100593986","phase-2-chemoimmunotherapy-for-alk-relapsedrefractory-alcl-100593986",false,"NCT07013565","Chemoimmunotherapy for ALK+ Relapsed\u002FRefractory ALCL","NYMC623: A Comprehensive Risk-adapted Chemommunotherapy Protocol of Emerging Immunotherapies for Relapsed\u002FRefractory Alk+ Anaplastic Large Cell Lymphoma (ACCELERATE)","ACCELERATE","Inclusion Criteria:\n\n* Patients must weigh ≥10 kilograms at the time of study enrollment.\n* Patients with relapsed or refractory histologically or cytologically proven ALK-positive anaplastic large cell lymphoma meeting Low or High Risk Criteria:\n\nLow Risk Cohort (LR cohort):\n\n* Any patient with FIRST RELAPSE \\> ONE YEAR from initial diagnosis of de novo ALK+ ALCL,\n* Common histology,\n* CD3 negative, AND\n* No prior exposure to vinblastine (VBL).\n\nHigh-Risk Cohort (HR cohort):\n\n* Any patient with RELAPSED OR PROGRESSIVE DISEASE less than ONE YEAR from initial diagnosis of de novo ALK+ ALCL,\n* Small cell\u002Fhistiocytic histology,\n* CD3 positive (homogeneous staining of CD3 positive T-cells)\n* Patients must have adequate organ function.\n* Patients must have performance status 60 or above.\n\nExclusion Criteria:\n\n* ALK-NEGATIVE anaplastic large cell lymphoma.\n* Patients with active leptomeningeal disease (lymphoma cells in CSF).\n* Previous treatment with vinblastine (only in patients in the LR cohort).\n* Female patients who are pregnant. Pregnancy tests must be obtained in girls who are post menarche.\n* Lactating females unless they have agreed not to breastfeed their infants.\n* Patients with Down syndrome.\n* Any patient with uncontrolled infection prior to study entry.\n* Any patient known to have primary or acquired immunodeficiency and\u002For prior solid organ transplant.","ALL","1 Year","39 Years",{"count":21,"type":22},20,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","Children, adolescents, and young adults (CAYA) with relapsed\u002Frefractory (R\u002FR) high-risk ALK+ Anaplastic Large Cell Lymphoma (ALCL) have a low incidence of overall survival. This clinical trial will investigate if a new FDA approved medication called Nivolumab (NIVO) (which is a checkpoint blockade immunotherapy) combined with chemotherapy based on the patients risk status to get the patient into the best response possible. Then patients will receive lower doses of chemoimmunotherapy and allogeneic stem cell transplantation (stem cells from another person). The investigators this this new treatment will improve survival rates in this high-risk population of patients.",[28],"Anaplastic Large Cell Lymphoma, ALK-Positive",[30,31],"ALCL","Relapsed ALCL","RECRUITING","2026-05-18",{"date":35,"type":36},"2026-05-20","ACTUAL",{"date":38,"type":36},"2025-08-07",{"date":40,"type":22},"2030-07-01",{"name":42,"class":43},"New York Medical College","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":52,"targetDuration":54,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":88,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":94,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},"100514411","a-registry-for-people-with-t-cell-lymphoma-100514411","NCT05978141","A Registry for People With T-cell Lymphoma","The T-cell Lymphoma Master Repository (TCLMR): A Prospective Databank of Patients With T-cell Lymphoma With Clinical Annotation and Matched Tumor Specimens","Inclusion Criteria:\n\n* Written informed consent\n* Adequate fresh or archival tumor biopsy or intent to obtain fresh tumor biopsy.\n* Pathologically-confirmed mature T- or natural killer (NK)-cell lymphoma meeting one of the following diagnostic criterion (based on WHO classification and NCCN guidelines):\n\n  * T-cell prolymphocytic leukemia\n  * T-cell large granular lymphocytic leukemia\n  * Chronic lymphoproliferative disorder of NK cells\n  * Aggressive NK-cell leukemia\n  * Systemic Epstein-Barr virus (EBV)-positive T-cell lymphoma of childhood\n  * Chronic active EBV infection of T- and NK-cell type, systemic form\n  * Hydroa vacciniforme-like lymphoproliferative disorder\n  * Adult T-cell leukemia\u002Flymphoma\n  * Extranodal NK\u002FT-cell lymphoma, nasal type\n  * Enteropathy-associated T-cell lymphoma\n  * Monomorphic epitheliotropic intestinal T-cell lymphoma\n  * Intestinal T-cell lymphoma, not otherwise specified (NOS)\n  * Indolent T-cell lymphoproliferative disorder of the gastrointestinal tract\n  * Hepatosplenic T-cell lymphoma\n  * Subcutaneous panniculitis-like T-cell lymphoma\n  * Mycosis fungoides (limited to those with ≥ stage IB disease and those receiving active therapy)\n  * Sézary syndrome\n  * Primary cutaneous anaplastic large cell lymphoma (receiving systemic therapy)\n  * Primary cutaneous Gamma-Delta T-cell lymphoma\n  * Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma\n  * Primary cutaneous acral CD8+ T-cell lymphoma (receiving systemic therapy)\n  * Peripheral T-cell lymphoma, not otherwise specified\n  * Angioimmunoblastic T-cell lymphoma\n  * Follicular T-cell lymphoma\n  * Nodal peripheral T-cell lymphoma with TFH phenotype\n  * Anaplastic large cell lymphoma, ALK-positive\n  * Anaplastic large cell lymphoma, ALK-negative\n  * Breast-implant associated anaplastic large cell lymphoma.\n* NOTE: Patients with diagnoses of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and\u002For primary cutaneous acral CD8+ T-cell lymphoma must be receiving systemic therapy.\n\nExclusion Criteria:\n\n* Patients with of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and\u002For primary cutaneous acral CD8+ T-cell lymphoma not receiving systemic therapy.\n* Inability to collect prospective data, measure response, or perform adequate follow-up assessments in the clinical judgment of the treating physician. NOTE: Repository participation does not exclude participation in clinical trials, nor does existing clinical trial participation exclude enrollment in the study herein outlined.",{"count":53,"type":22},1000,"10 Years","OBSERVATIONAL","The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more about how to improve outcomes for people with T-cell lymphoma.",[58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,28,86,87],"T-cell Lymphoma","NK-Cell Lymphoma","T-cell Prolymphocytic Leukemia","T-cell Large Granular Lymphocytic Leukemia","Chronic Lymphoproliferative Disorder of NK Cells","Aggressive NK-cell Leukemia","Systemic Epstein-Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood (Disorder)","Systemic Epstein Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood","Chronic Active EBV Infection of T-and NK-Cell Type, Systemic Form","Hydroa Vacciniforme-Like Lymphoproliferative Disorder","Adult T-cell Leukemia\u002FLymphoma","Extranodal NK\u002FT-cell Lymphoma, Nasal Type","Enteropathy-associated T-cell Lymphoma","Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma","Intestinal T-Cell Lymphoma, Not Otherwise Specified","Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract","Hepatosplenic T-cell Lymphoma","Subcutaneous Panniculitis-Like T-Cell Lymphoma","Mycosis Fungoides","Sezary Syndrome","Primary Cutaneous Anaplastic Large Cell Lymphoma","Primary Cutaneous T-cell Lymphoma","Primary Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell Lymphoma","Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma","Peripheral T-Cell Lymphoma, Not Otherwise Specified","Angioimmunoblastic T-cell Lymphoma","Follicular T-Cell Lymphoma","Nodal Peripheral T-Cell Lymphoma With TFH Phenotype","Anaplastic Large Cell Lymphoma, ALK-negative","Breast Implant-Associated Anaplastic Large Cell Lymphoma",[89,90,91,92,93],"23-190","T-cell lymphoma","Memorial Sloan Kettering Cancer Center","T-cell Lymphoma Master Repository","TCLMR",{"date":35,"type":36},{"date":96,"type":36},"2023-07-27",{"date":98,"type":22},"2030-07-27",{"name":91,"class":43},26,{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":17,"minAge":109,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":23,"phases":113,"briefSummary":115,"conditions":116,"keywords":122,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":136},"100529662","phase-1-constitutive-il7r-c7r-modified-banked-allogeneic-cd30car-ebvsts-for-cd30-positive-lymphomas-100529662","NCT06176690","Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas","Constitutive IL7R (C7R) Modified Banked Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes (CD30.CAR-EBVSTs) in Patients With Relapsed or Refractory CD30-Positive Lymphomas","CABAL2","Inclusion Criteria:\n\n1. Diagnosis and clinical course falling into one of the following categories:\n\n   1. Hodgkin lymphoma\n   2. CD30+ aggressive B-cell lymphoma\n   3. ALK-negative anaplastic T cell lymphoma or other peripheral T- cell lymphoma\n   4. ALK-positive anaplastic T cell lymphoma\n2. CD30-positive tumor as assayed in a CLIA certified Pathology Laboratory.\n3. Age 12 to 75.\n4. Bilirubin less than or equal to 2 times the upper limit of normal (except for Gilbert syndrome, where the criteria will be Bilirubin less than or equal to 3 times the upper limit of normal).\n5. AST less than 3 times the upper limit of normal.\n6. Estimated GFR \\> 70 mL\u002Fmin.\n7. Pulse oximetry of \\> 90% on room air\n8. Karnofsky or Lansky score of \\> 60%.\n9. Recovered from all acute non-hematologic toxic effects of all prior chemotherapy.\n10. Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded. The male partner should use a condom.\n11. Informed consent explained to, understood by and signed by patient or guardian. Patient or guardian given a copy of the informed consent form.\n\nExclusion Criteria:\n\n1. Received an investigational cell therapy or vaccine within the past 6 weeks.\n2. Received an investigational small molecule drug within the past 2 weeks.\n3. Received anti-CD30 antibody-based therapy within the previous 4 weeks.\n4. History of hypersensitivity reactions to murine protein-containing products.\n5. Pregnant or lactating.\n6. Tumor in a location where enlargement could cause airway obstruction (determined at the investigators' discretion).\n7. Current use of systemic corticosteroids at a dose equivalent to or higher than 10 mg\u002Fday of prednisone.\n8. Active significant, uncontrolled bacterial, viral or fungal infection.\n9. Symptomatic cardiac disease (NYHA Class III or IV disease).","12 Years","75 Years",{"count":112,"type":22},90,[114],"PHASE1","This study involves patients with diffuse large B cell lymphoma (DLBCL), natural killer\u002FT-cell lymphoma (NKTL), or classical Hodgkin lymphoma (cHL) (referred to collectively as lymphoma) whose disease has returned or not responded to treatment.\n\nPrevious research combined antibodies and T cells to treat cancer. Antibodies bind to foreign substances, and T cells are infection-fighting white blood cells that can kill tumor cells. Both approaches have shown promise but have not been sufficient to cure most patients. In prior studies, an antibody targeting CD30, a protein found on some T cells and cancer cells, was joined to T cells through gene transfer to create CD30.CAR T cells.\n\nAnother study showed encouraging responses using CD30.CAR T cells made from a patient's own blood and returned to the same patient (autologous cells). In an ongoing study, patients have been treated with CD30.CAR T cells derived from healthy donors (allogeneic cells), allowing use of banked cells without individualized manufacturing. This approach has shown promising clinical activity with no safety concerns to date.\n\nIn this study, investigators are evaluating CD30.CAR-EBVST cells modified with an additional molecule called C7R, which has been shown in laboratory studies to enhance anti-cancer effects. The study aims to assess the safety and effectiveness of these allogeneic, banked C7R-modified CD30.CAR-EBVST cells and determine whether they may help treat lymphoma.\n\nAs an added safety measure, the modified T cells include a marker called iC9. If significant side effects occur, patients may receive rimiducid, which can eliminate the infused T cells. Rimiducid is not yet FDA approved but has been tested in patients without significant side effects.",[117,118,28,119,86,120,121],"CD30-Positive Diffuse Large B-Cell Lymphoma","Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type","Peripheral T-cell Lymphoma","Non-Hodgkin Lymphoma","Hodgkin Lymphoma",[123,124,125,126],"CD30-Positive Lymphoma","Hodgkin lymphoma","non-Hodgkin lymphoma","CD30 CAR","2026-04-07",{"date":129,"type":36},"2026-04-13",{"date":131,"type":36},"2025-10-27",{"date":133,"type":22},"2043-06-27",{"name":135,"class":43},"Baylor College of Medicine",2,{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":23,"phases":148,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":136},"100433552","phase-1-brigatinib-in-pediatric-and-young-adult-patients-with-alk-alcl-imt-or-other-solid-tumors-100433552","NCT04925609","Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors","A Phase I\u002FII Study of Brigatinib in Pediatric and Young Adult Patients With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors","Briga-PED","Inclusion Criteria:\n\n1. Patients must be 1 and \\\u003C 26 years of age at the time of enrollment, and able to swallow brigatinib tablets at the time of enrollment, with a minimum weight of 10 kg. Note: for phase 1 only patients ≤18 years old will be eligible, A liquid formulation for children with a weight lower than 10 kg or for those that cannot swallow tablets is in development.\n2. Patients must have a confirmed diagnosis of cancer histologically at baseline. In patients where a repeat biopsy at relapse (or moment of refractory disease) is considered not feasible by the treating physician, archived material from diagnosis needs to be available for central review.\n3. Patients are required to provide prior results showing an activating ALK aberration in the tumor per local laboratory results, and material needs to be available for central laboratory confirmation of ALK status. For ALK+ ALCL, detection of ALK with immunohistochemistry (IHC) is sufficient for inclusion, all others require molecular evidence of a ALK fusion gene or mutation by FISH, PCR or NGS. ALK detection will be confirmed centrally with FISH.\n4. For Phase 1:\n\n   * Patients with ALCL must be relapsed\u002Frefractory or intolerant to standard therapies. Refractory disease for ALCL is defined as:\n\n     o no response to ALCL99\u002Fother standard of care chemotherapy (SD or PD of measurable lesions), and\u002For\n\n     o MRD-positivity by qualitative PCR for NPM-ALK prophase after one block ALCL99\u002Fother standard of care chemotherapy (before the second course of chemotherapy).\n   * Patients with relapsed\u002Frefractory (R\u002FR) IMT must not be suitable for curative surgical resection without causing mutilation. Newly diagnosed patients with unresectable ALK+ IMT, or when surgery would imply severe mutilation may also be included, as well as metastatic disease.\n   * Patients with other solid tumors (excluding IMT) must have relapsed or refractory disease.\n5. For Phase 2, patients must have measurable and\u002For evaluable disease:\n\n   * Patients with ALCL must be relapsed\u002Frefractory. Refractory disease for ALCL is defined as:\n\n     * no response to ALCL99\u002Fother standard of care chemotherapy (SD or PD of measurable lesions), and\u002For\n     * MRD-positivity by qualitative PCR for NPM-ALK prophase after one block ALCL99\u002Fother standard of care chemotherapy (before the second course of chemotherapy).\n   * Patients with R\u002FR IMT Relapsed\u002Frefractory ALK+ IMT, or newly diagnosed, including advanced and metastatic, ALK+ IMT which cannot be surgically resected without causing mutilation\n6. Performance Status: Karnofsky performance status ≥40% for patients \\>16 years of age or Lansky Play Scale ≥40% for patients ≤16 years of age.\n7. Patients must not be receiving other investigational medications (defined as medicinal products not yet approved for any indications, including alternative\u002Fherbal therapies) within 30 days of first dose of study drug or while on study.\n8. For patients receiving prior therapy:\n\n   * Patients who already received previous treatment with ALK inhibitors except for brigatinib can be included in this study.\n   * Patients must have recovered to Grade \\\u003C2 NCI CTCAE v5.0 or to baseline, from any nonhematologic toxicities (except alopecia and peripheral neuropathy) due to previous therapy.\n   * Patients who relapsed while receiving cytotoxic therapy: at least 14 days must have passed since the completion of the last dose of chemotherapy before the first dose of brigatinib can be given.\n   * Patients who have experienced relapse after a prior HSCT are eligible, provided they have no evidence of acute or chronic graft-versus-host disease (GVHD), are not receiving GVHD prophylaxis or treatment, and are at least 45 days posttransplant at the time of enrollment.\n   * Hematopoietic growth factors: before the first dose of brigatinib, at least 7 days must have passed since completion of therapy with granulocyte colony-stimulating factor or other growth factors, and at least 14 days must have passed since completion of therapy with pegfilgrastim.\n   * Biologics and Targeted Therapies:\n\n     o Immunotherapy: Before the first dose of brigatinib, at least 30 days must have passed after the completion of any type of immunotherapy, (i.e. monoclonal antibodies \\[anti-PD1\u002FPDL1\\], tumor vaccines, chimeric antigen receptor \\[CAR\\] T cells, etc.).\n\n     o Other: before the first dose of brigatinib, at least 7 days must have passed since the last dose of a biologic agent. For agents that have known adverse events (AEs) occurring beyond 7 days after administration, this period must be extended beyond the time during which AEs are known to occur. The duration of this interval must be discussed with the sponsor's medical monitor\u002Fdesignee.\n\n     o Immunosuppressive therapy: Before the first dose of brigatinib, at least 14 days must have passed after the completion of immunosuppressive therapy (including regimens following stem cell transplant).\n\n     o For symptomatic patients that urgently need relief (i.e. airway obstruction), therapeutic doses of corticosteroids may be administered for a short course (up to 5 days).\n\n     o Radiotherapy (XRT): No washout period is necessary for radiation given to any extramedullary site other than the CNS and lungs; ≥45 days must have passed if patient received prior total body irradiation or craniospinal or cranial XRT; ≥28 days must have passed if patient received radiotherapy to the lung. For patients receiving XRT to both lungs, or in case of stereotactic radiotherapy, the PIs should be consulted before inclusion.\n9. Patients must meet the organ function and system function requirements as stated below:\n\n   * Patients must have adequate renal and hepatic function as indicated by the following laboratory values:\n\n     o Patient's serum creatinine must be ≤ 1.5 x institutional upper limit of normal (ULN) according to age. If the serum creatinine is greater than 1.5 x institutional ULN, the patient must have a radioisotope GFR ≥ 70mL\u002Fmin\u002F1.73m2\n     * Adequate liver function defined as: direct bilirubin ≤1.5 times the upper limit of normal (ULN) for age AND AST and ALT must be ≤5 times the ULN for age (unless related to involvement of the liver or histiocytic\u002Fmacrophage inflammatory process).\n   * No clinical, radiological or laboratory evidence of pancreatitis, including o Serum lipase must be \\\u003C2 × the ULN, and\n\n     o Serum amylase must be \\\u003C2 × the ULN.\n   * Absolute neutrophil count: ≥0.75 × 10 9\u002FL, except in case of macrophage activation syndrome (MAS) or bone marrow involvement.\n   * Platelet count o In phase 1: Platelet count: ≥75 × 10\\^9\u002F L, except in case of MAS or bone marrow involvement o In phase 2: : Platelet count: ≥75 × 10\\^9\u002F L, except in case of MAS or bone marrow involvement. For patients post SCT, platelet count ≥50 × 10\\^9\u002F L is accepted.Hemoglobin ≥8 g\u002FdL or 5.0 mmol\u002FL (red blood cell \\[RBC\\] transfusions to achieve this value are allowed with the condition that the patient has no signs of active bleeding or hemolysis).\n10. Adequate cardiac function defined as shortening fraction ≥27% by echocardiogram OR left ventricular ejection fraction of ≥50% by multigated acquisition scan.\n11. Normal QT interval corrected per Fridericia method (QTcF) on screening electrocardiogram (ECG), defined as QTcF of ≤450 ms.\n12. Have a life expectancy of ≥3 months.\n13. Female patients of childbearing potential must have a negative urine or serum pregnancy test confirmed prior to enrollment.\n14. Female patients with infants must agree not to breastfeed their infants while on this study.\n15. Contraception:\n\n    • Male and female patients of child-bearing potential must agree to use, an effective method for male and highly effective method for female, of contraception approved by the investigator during the study, following the CTFG recommendations, for at least 8 months for females and for at least 5 months for males after the last dose of brigatinib.\n\n    • Highly effective methods of contraception include (but not exclusively) the following contraceptive methods:\n\n    o combined (estrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation\n    * progestogen-only hormonal contraception associated with inhibition of ovulation\n    * intrauterine device (IUD), intrauterine hormone-releasing system (IUS), sexual abstinence.\n16. Voluntary written informed consent according to law and regulations\n\n    \\-\n\nExclusion Criteria:\n\nPatients meeting any of the following exclusion criteria are not to be enrolled in the study:\n\n1. Patients receiving systemic treatment with strong or moderate CYP3A inhibitors or inducers within 14 days or five half-life times whichever the less prior to the first dose of study drug (refer to Section 5.2 for a list of example medications).\n2. Diagnosis of another concurrent primary malignancy.\n3. Clinically significant cardiovascular disease, including any of the following:\n\n   * Myocardial infarction or unstable angina within 6 months of study entry.\n   * History of or presence of heart block, and\u002For clinically significant ventricular or atrial arrhythmias.\n   * Uncontrolled hypertension defined as persistent elevation of systolic and\u002For diastolic blood pressures to ≥95th percentile based on age, sex, and height percentiles despite appropriate antihypertensive management.\n4. Planned non-protocol chemotherapy, radiation therapy, another investigational agent, or immunotherapy while patient is on study treatment.\n5. Any illness that affects gastrointestinal absorption.\n6. Ongoing or active systemic infection, active seropositive HIV, or known active hepatitis B or C infection.\n7. Any pre-existing condition or illness that, in the opinion of the investigator or sponsor, would compromise patient safety or interfere with the evaluation of the safety or efficacy of brigatinib.\n8. Patients with a history of cerebrovascular ischemia\u002Fhemorrhage with residual deficits are not eligible (patients with a history of cerebrovascular ischemia\u002Fhemorrhage remain eligible provided all neurologic deficits have resolved).\n9. Uncontrolled seizure disorder (patients with seizure disorders that do not require antiepileptic drugs, or are well controlled with stable doses of antiepileptic drugs are eligible).","25 Years",{"count":147,"type":22},65,[114,25],"This is an open-label, phase I-II dose-escalation and expansion study designed to define the recommended dose of brigatinib as monotherapy in pediatric and young adult patients with ALK+ ALCL, IMT or other solid tumors and to evaluate the pharmacokinetics (PK), (long-term) safety, and efficacy of brigatinib in these children.",[28,151,152],"Inflammatory Myofibroblastic Tumor","Other Solid Tumor","2025-11-27",{"date":155,"type":36},"2025-12-05",{"date":157,"type":36},"2022-08-18",{"date":159,"type":22},"2033-12",{"name":161,"class":43},"Princess Maxima Center for Pediatric Oncology"]